In headline news today, Agilent (market cap $50B) will acquire Proscia in a deal for $240M in cash. See news below.
I've had a number of blogs recently on strategies in digital pathology. Here's a lookback to a white paper I wrote in May 2026 comparing the digital pathology business strategies of Philips and Roche. It comprises two deep-dive reports by AI, one by Claude and one by Chat GPT. Find it here:
https://www.discoveriesinhealthpolicy.com/2026/05/can-ai-write-deep-strategic-business.html
###
Guest Author: Chat GPT looks into the deal for us.
###
Agilent’s planned acquisition of Proscia illustrates a broader contest in cancer diagnostics: who will supply the software connecting laboratory instruments, tissue images, and artificial intelligence? On October 13, 2026, Agilent announced an agreement to buy the digital pathology company for $240 million in cash, plus up to $30 million in performance milestones. Closing is expected early in Agilent’s fiscal 2027. Announcement here.
Agilent is a global supplier of laboratory instruments, reagents, software, and services, with fiscal 2025 revenue of $6.95 billion. Its pathology business includes Dako, the cancer diagnostics company acquired in 2012, and Biocare Medical, whose acquisition closed in June 2026. These businesses supply staining instruments and reagents that help laboratories identify biological markers in tissue. Proscia would extend that presence further into the digital work performed after slides are prepared.
Philadelphia-based Proscia develops and supplies Concentriq, a software platform for managing, viewing, and analyzing digitized pathology images. Scanners create the images; Concentriq connects them with laboratory systems, pathologists, and AI applications. According to Agilent, by means of Concentriq software, Proscia serves more than 4,000 laboratories, hospitals, and clinics, plus 16 of the 20 largest pharmaceutical companies. Its trailing annual revenue exceeded $18 million. The companies have already worked together under a distribution agreement dating to 2022. That distribution channel is now tightened into an acquisition.
The strategic logic is straightforward. Owning software used throughout a laboratory’s daily work could deepen Agilent’s customer relationships, generate recurring revenue, and create additional opportunities in pharmaceutical research and companion diagnostics. A platform connecting tissue preparation with image interpretation could also make it easier to develop and deploy quantitative biomarker tests. These are business opportunities, however, rather than demonstrated financial benefits of the acquisition.
The price reflects substantial expectations. Using $18 million as a reference, the upfront payment represents approximately 13.3 times annual sales; the actual multiple is lower because reported revenue exceeds that figure. Agilent describes Proscia as a growing, high-margin software business but provides no numerical growth, margin, or earnings targets in the announcement. Buyers are therefore being asked to assess the strategic potential with limited financial detail.
For Leica Biosystems, part of Danaher, the implications include both competition and cooperation. Proscia’s August 2026 FDA clearance included compatibility with Leica’s Aperio GT 450 DX scanner. Agilent could consequently gain software revenue from laboratories using Leica hardware. That makes preserving interoperability commercially important: supporting competing instruments can expand the software’s market. Roche likewise supports third-party algorithms through its Digital Pathology Open Environment, demonstrating that these competitive boundaries already overlap.
Tempus offers another comparison. The precision-medicine and AI company acquired Paige in August 2025, emphasizing its pathology images, technical expertise, and AI capabilities. Strategically, Tempus approached pathology from data and computational medicine; Agilent approaches it from laboratory infrastructure and diagnostics. Both transactions suggest that pathology software is becoming an important component of larger healthcare businesses.
For independent AI developers, larger platforms could offer broader distribution while gaining greater influence over commercial terms and customer access. (Compare: Cerner/Epic in EHRs).
For laboratories, the practical questions remain concrete: Will integration become easier? Will pathologists save time? Will new capabilities justify their cost? Agilent’s investment strengthens its ability to compete for that business; execution will determine the return.
##
What's Interesting or Surprising about Agilent-Proscia?
Agilent is paying for a strategic position well ahead of current revenue. Proscia generates just over $18 million annually; the $240 million upfront price implies roughly 13 times sales, using $18 million as the reference. That revenue is only about 0.3% of Agilent’s annual revenue. The investment’s importance lies in what Proscia could enable across Agilent’s business. www.agilent.com
The central asset is the software pathologists work in—not simply an AI algorithm. Concentriq connects images, laboratory systems, people, and analytical applications. Strategically, owning that daily workspace could give Agilent influence over how numerous AI products reach customers. Its distribution relationship with Proscia since 2022 also means this follows several years of commercial experience together. www.agilent.com
Agilent could benefit when a laboratory buys a competitor’s scanner. Proscia’s FDA-cleared platform supports Leica’s Aperio GT 450 DX. That creates an unusual competitive relationship: Leica supplies the scanning hardware, while Agilent could supply the software used with its images. Preserving compatibility with rival equipment therefore has direct commercial value. www.globenewswire.com
The pharmaceutical footprint is striking for such a small company. Proscia serves 16 of the top 20 pharmaceutical companies, according to the announcement. That gives Agilent an established software presence in drug-development organizations—potentially valuable for biomarker research and companion diagnostics. However, customer reach alone does not reveal contract size or depth of adoption. www.agilent.com
The deal follows a much larger move by Roche into the same territory. Roche announced its PathAI acquisition in May for $750 million upfront, potentially $1.05 billion. Alongside Tempus–Paige, these transactions suggest a shift toward pathology software being owned by larger diagnostics and data businesses. An important strategic question is how those platforms will balance their parent companies’ priorities with the openness customers and independent AI developers value. www.roche.com
##
Review of Deals
The Broader Picture: Eight Major Deals and Financings in Digital Pathology
Agilent’s purchase of Proscia joins a substantial wave of acquisitions, investment, and consolidation. Eight notable transactions from 2025–2026 illustrate how laboratory manufacturers, software companies, and investors are positioning themselves:
Agilent–Proscia: $240 million, plus up to $30 million in milestones. Announced October 13, 2026. Agilent agreed to acquire Proscia, the company that makes Concentriq, adding digital pathology software to its tissue-diagnostics portfolio. Announcement.
Roche–PathAI: $750 million upfront, potentially $1.05 billion. Announced May 7, 2026. Roche agreed to acquire PathAI, including its AISight image-management software, AI capabilities, and pharmaceutical research services. This would deepen Roche’s presence across laboratory workflow and computational diagnostics. Announcement.
Agilent–Biocare Medical: $950 million. Announced March 2026 and completed in June. This is an adjacent tissue-pathology acquisition: Biocare supplies staining instruments, antibodies, and reagents. Together, Biocare and Proscia would expand Agilent’s presence from slide preparation through digital review. Announcement; completion.
Grundium–Visiopharm: price undisclosed. Announced May 21, 2026. Finnish scanner manufacturer Grundium acquired Danish pathology AI and image-analysis company Visiopharm, combining slide digitization with quantitative tissue analysis and biomarker applications. Announcement.
Tempus–Paige: $81.25 million, predominantly in stock, plus assumed cloud commitments. Announced August 22, 2025. Tempus acquired Paige’s pathology AI technology and expertise, alongside a dataset of nearly seven million digitized slides with associated information. Announcement.
Evident–Pramana: price undisclosed. Completed August 27, 2025. Evident, the former Olympus microscopy business, acquired Pramana’s autonomous slide-scanning technology, strengthening its capabilities in automated image acquisition and quality control. Announcement.
Waiv, formerly Owkin Dx: $35 million Series A. Final closing announced April 24, 2026. Investors backed development and commercialization of AI-based oncology tests, including applications extracting biomarker and prognostic information from pathology images. Announcement.
Aiforia: €20 million venture-debt agreement. Announced July 31, 2026. European Investment Bank financing supports the Finnish pathology AI company’s product development and commercial expansion. Funding is available in tranches subject to milestones. Announcement.
The Latest Paige Development: Channel through Leica Aperio
On September 24, 2026, Leica Biosystems announced the addition of Tempus’s Paige PanCancer Detect and Paige Prostate products to its Aperio AI Store. PanCancer Detect identifies suspicious areas across more than 40 cancer types; the prostate suite supports detection, grading, quantification, and assessment of perineural invasion. The applications operate within Leica’s Aperio HALO AP software workflow, developed with Indica Labs. Leica announcement.
This is a useful example of cooperation across corporate boundaries: Tempus owns Paige, while Leica provides another distribution channel. But the announcement explicitly labels these offerings research use only, not for diagnostic or clinical use. It therefore illustrates both progress toward integrated pathology AI and the remaining distance to broadly deployable, FDA-authorized diagnostic and report-drafting systems.
###
Review of Funding Events
These two funding deals bring the previous list to ten, and both fall within the past 12 months:
Waiv, formerly Owkin Dx — April 24, 2026: $35 million Series A financing. Initial investors OTB Ventures and Alpha Intelligence Capital were joined by CRB Health Tech and others. Waiv develops AI tests that extract biomarker and prognostic information from pathology images, including breast cancer risk assessment and colorectal cancer MSI screening. Funding supports development and commercial expansion. The $35 million is the completed round’s total, including its extension. Company announcement. waiv.com
Aiforia — July 31, 2026: €20 million venture-debt financing agreement with the European Investment Bank. The Finnish pathology AI company secured financing for image-analysis product development and international commercial expansion. This is debt financing, available in three tranches subject to revenue and other milestones, rather than a conventional VC equity round. EIB announcement. eib.org
My bias is that FDA-authorized systems that analyze slides and prepare draft reports before the pathologist opens the case will blow the roof off digital pathology’s growth—and that this opportunity remains underappreciated. The compelling product is a substantially completed first pass: findings, measurements, supporting images, and a report ready for physician review. Agilent’s acquisition of Proscia deserves attention through that lens.
Radiology offers an early indication of the potential. DeepHealth’s FDA-cleared breast ultrasound application analyzes images and generates reports for physician review. The company reports a 37% reduction in interpretation time in its FDA-submitted reader study—close to 40%. That is a result for a defined examination and study setting, rather than a reduction in the radiologist’s entire workday, but its commercial significance is considerable. DeepHealth announcement.
FDA is also investing in the methods needed to evaluate these products. A $1.29 million research contract awarded to Cognita Imaging will test approaches to evaluating AI-generated radiology reports across approximately one million examinations, with radiologists reviewing important discrepancies. This is regulatory-science research, not authorization of a product, but it addresses an essential bottleneck: how to assess the quality of an entire generated report at scale. Contract announcement.
Where does Agilent fit? Its proposed $240 million purchase of Proscia, plus potential milestones, combines a large diagnostics manufacturer with software positioned inside the pathologist’s workflow. Agilent brings laboratory relationships, tissue-diagnostics products, and experience commercializing regulated tests. Proscia brings the infrastructure connecting slides, case information, analytical applications, and the physician’s workstation. The strategic inference is that this combination could support development and distribution of a report-drafting product. Acquisition announcement.
Proscia’s recent product descriptions make that possibility concrete. Its fifth-generation Concentriq architecture connects images with clinical context, runs relevant analyses automatically, and prepares work for the expert. Its launch announcement describes assembling reportable findings for pathologist confirmation. Those capabilities are relevant building blocks for a case that arrives already analyzed and partially documented. Proscia’s architecture explanation.
The regulatory gap is equally revealing. Proscia explicitly distinguishes these research-use-only capabilities from Concentriq AP-Dx, its separate FDA-cleared product for primary diagnosis. Clearance of the viewer does not authorize every AI application operating within it. The public materials reviewed do not establish an FDA-authorized comprehensive draft-report system, and Agilent’s announcement makes no specific commitment to deliver one. Product-status disclosures.
This is where pathology’s dependence on RUO-based, locally assembled and validated solutions can impose a crippling scaling penalty on itself. Dependence on RUO: it's not for nothing that we read of 1400 FDA radiology apps and 5 pathology ones (all else RUO.)
- Each implementation can become another development project. A manufacturer-supported, FDA-authorized product could concentrate much of the evidence generation, maintenance, and change management centrally. Local implementation checks would remain—CAP still emphasizes validation of digital diagnostic workflows—but hospitals could adopt a defined product with established performance claims. CAP guidance.
The decisive commercial test would be net physician time saved while maintaining diagnostic quality, including time spent checking and correcting drafts. A convincing result could make digital adoption easier to justify from operating economics, even before considering separate AI reimbursement.
Agilent has acquired an opportunity to pursue that result. The milestone worth watching is a product label, clinical study, and everyday workflow demonstrating that a pathologist can open a prepared case and finish it substantially faster.
